Targeting Oncogenic Mutant p53 for Cancer Therapy.

摘要: Among genetic alterations in human cancers, mutations the tumor suppressor p53 gene are most common, occurring over 50% of cancers. The majority missense and result accumulation dysfunctional protein tumors. These mutants frequently have oncogenic gain-of-function activities exacerbate malignant properties cancer cells, such as metastasis drug resistance. Increasing evidence reveals that stabilization mutant tumors is crucial for its activities, while depletion attenuates cells. Thus, an attractive druggable target therapy. Different approaches been taken to develop small-molecule compounds specifically p53. include restore wild-type conformation transcriptional activity p53, induce inhibit downstream pathways synthetic lethality In this review article, we comprehensively discuss current strategies targeting with special focus on those reducing levels.